Teva Pharmaceutical Industries — TEVA
| Close Price | Market Cap | P/E Ratio | Forward P/E Ratio | Implied Growth* | Implied Forward Growth* | Dividend | P/B Ratio |
|---|---|---|---|---|---|---|---|
| $18.73 | $21.71B | - | 6.8 | N/A | 0.2% | - | 3.1 |
Revenue & Net Income
| Date | Revenue | Net Income | EPS | Revenue Change | Net Income Change | EPS Change | |
|---|---|---|---|---|---|---|---|
| 0 | 2020-12-31 | $16.7B | $-4.0B | $-3.64 | N/A | N/A | N/A |
| 1 | 2021-12-31 | $15.9B | $417.0M | $0.38 | -4.7% | -110.5% | -110.4% |
| 2 | 2022-12-31 | $14.9B | $-2.4B | $-2.12 | -6.0% | -686.6% | -657.9% |
| 3 | 2023-12-31 | $15.8B | $-559.0M | $-0.50 | 6.2% | -77.1% | -76.4% |
| 4 | 2024-12-31 | $16.5B | $-1.6B | $-0.50 | 4.4% | 193.2% | 0.0% |
| 5 | TTM 2025-03-31 | $16.6B | $-1.3B | $-1.15 | 0.4% | -21.5% | 130.0% |
| 6 | Average | 0.1% | -140.5% | -142.9% |
EPS
Forecasts
Y/Y % Change
TEVA Year-over-Year Growth
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Average | |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth (%) | -4.7% | -6.0% | 6.2% | 4.4% | 2.0% | 0.4% | 0.4% | |
| Revenue Analysts (#) | 0 | 0 | 0 | 0 | 0 | 5 | 5 | |
| EPS Growth (%) | -110.5% | -686.6% | -77.1% | 193.2% | -276.8% | 8.4% | -158.2% | |
| EPS Analysts (#) | 0 | 0 | 0 | 0 | 0 | 7 | 7 |
Expenses
| Year | Revenue ($) | Cost of Revenue ($) | R&D ($) | Sales & Marketing ($) | G&A ($) | SG&A ($) | Facilities / D&A ($) |
|---|---|---|---|---|---|---|---|
| 2021 | $15.9B | $7.0B | $967.0M | $2.4B | $1.1B | $3.5B | $1.3B |
| 2022 | $14.9B | $6.6B | $838.0M | $2.3B | $1.2B | $3.4B | $1.3B |
| 2023 | $15.8B | $7.0B | $953.0M | $2.3B | $1.2B | $3.5B | $1.2B |
| 2024 | $16.5B | $7.4B | $998.0M | $2.5B | $1.2B | $3.7B | $1.1B |
| TTM | $16.6B | $7.4B | $978.0M | $2.6B | $1.2B | $3.8B | $1.0B |
| Year | Revenue Change (%) | Cost of Revenue Change (%) | R&D Change (%) | Sales & Marketing Change (%) | G&A Change (%) | SG&A Change (%) | Facilities / D&A Change (%) |
|---|---|---|---|---|---|---|---|
| 2022 | -6.01 | -4.46 | -13.34 | -6.75 | 7.37 | -2.35 | -1.65 |
| 2023 | 6.16 | 6.07 | 13.72 | 3.13 | -1.53 | 1.54 | -11.85 |
| 2024 | 4.41 | 5.32 | 4.72 | 8.78 | -0.09 | 5.83 | -8.15 |
| TTM | 0.50 | -0.88 | -2.00 | 0.43 | 3.53 | 1.40 | -3.40 |
No unmapped expenses.
Segment Performance
SEGMENTS v2025-09-09 · 2025-09-05 15:07 UTC — Values are shown in a single scale for this table: $B. TTM values are bold. “% of Total (TTM)” shows revenue mix.
| Segment | 2022 Rev ($B) | 2022 OI ($B) | 2023 Rev ($B) | 2023 OI ($B) | 2024 Rev ($B) | 2024 OI ($B) | TTM Rev ($B) | TTM OI ($B) | % of Total (TTM) |
|---|---|---|---|---|---|---|---|---|---|
| Product | 25.5B | 0.00B | 26.0B | 0.00B | 28.9B | 0.00B | 29.1B | 0.00B | 59.4% |
| Generics Medicians Including Otc And Biosimilars | 8.60B | 0.00B | 8.73B | 0.00B | 9.46B | 0.00B | 9.34B | 0.00B | 19.1% |
| Distribution Service | 3.04B | 0.00B | 3.23B | 0.00B | 3.15B | 0.00B | 3.12B | 0.00B | 6.4% |
| Austedo | 0.97B | 0.00B | 1.24B | 0.00B | 1.69B | 0.00B | 1.96B | 0.00B | 4.0% |
| Anda | 1.47B | 0.00B | 1.58B | 0.00B | 1.54B | 0.00B | 1.51B | 0.00B | 3.1% |
| Other Products | 1.19B | 0.00B | 1.82B | 0.00B | 1.38B | 0.00B | 1.28B | 0.00B | 2.6% |
| Product And Service Other | 0.86B | 0.00B | 1.14B | 0.00B | 0.73B | 0.00B | 0.69B | 0.00B | 1.4% |
| Ajovy | 0.38B | 0.00B | 0.43B | 0.00B | 0.51B | 0.00B | 0.61B | 0.00B | 1.2% |
| C O P A X O N E | 0.69B | 0.00B | 0.59B | 0.00B | 0.50B | 0.00B | 0.45B | 0.00B | 0.9% |
| License | 0.42B | 0.00B | 1.36B | 0.00B | 0.35B | 0.00B | 0.38B | 0.00B | 0.8% |
| Respiratory Product | 0.27B | 0.00B | 0.27B | 0.00B | 0.24B | 0.00B | 0.23B | 0.00B | 0.5% |
| Uzedy | – | – | 0.02B | 0.00B | 0.12B | 0.00B | 0.20B | 0.00B | 0.4% |
| Bendeka And Treanda | 0.31B | 0.00B | 0.24B | 0.00B | 0.17B | 0.00B | 0.16B | 0.00B | 0.3% |
SEGMENTS v2025-09-09 · 2025-09-05 15:07 UTC — Values are shown in a single scale for this table: $B. TTM values are bold. “% of Total (TTM)” shows revenue mix.
| Segment | 2022 Rev ($B) | 2022 OI ($B) | 2023 Rev ($B) | 2023 OI ($B) | 2024 Rev ($B) | 2024 OI ($B) | TTM Rev ($B) | TTM OI ($B) | % of Total (TTM) |
|---|---|---|---|---|---|---|---|---|---|
| United States | 14.0B | 3.87B | 15.5B | 4.79B | 16.1B | 4.59B | 16.6B | 5.27B | 47.9% |
| Europe | 9.05B | 2.99B | 9.67B | 2.96B | 10.2B | 3.15B | 10.4B | 3.05B | 30.0% |
| International Markets | 7.06B | 1.08B | 7.05B | 0.93B | 7.39B | 0.88B | 6.76B | 0.84B | 19.5% |
| Other Activities | 1.04B | 0.00B | 0.93B | 0.00B | 0.94B | 0.00B | 0.89B | 0.00B | 2.6% |
| Corporate | 0.00B | 3.97B | 0.00B | 4.34B | 0.00B | 4.31B | 0.00B | 4.58B | 0.0% |
| All Other Segments | 0.00B | 0.17B | 0.00B | 0.02B | 0.00B | 0.02B | 0.00B | -0.04B | 0.0% |
Balance Sheet
| Metric | Value | |
|---|---|---|
| 0 | Total Assets | $38,415M |
| 1 | Cash | $1,697M |
| 2 | Total Liabilities | $32,146M |
| 3 | Total Debt | $16,939M |
| 4 | Total Equity | $6,262M |
| 5 | Debt to Equity Ratio | 2.71 |
EPS & Dividend
Valuation
| Share Price | Treasury Yield | Estimates | Fair Value (P/E) | Fair Value (P/S) | Current P/S |
|---|---|---|---|---|---|
| $16.95 | 4.4% | Nicks Growth: 0% Nick's Expected Margin: 5% FINVIZ Growth: 7% |
Nicks: 6 Finviz: 13 |
Nick's: 0.320 | 1.2 |
| Basis | Year | Nicks Valuation | Nicks vs Share Price | Finviz Valuation | Finviz vs Share Price |
|---|---|---|---|---|---|
| $14.10 RevPS | TTM | $4.51 | -73.4% | $9.45 | -44.2% |
| $2.51 EPS | 2025 | $16.05 | -5.3% | $33.65 | 98.5% |
| $2.72 EPS | 2026 | $17.39 | 2.6% | $36.47 | 115.2% |
Implied Growth
| Average | Median | Std Dev | Current | Percentile | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| TTM | Forward | TTM | Forward | TTM | Forward | TTM | Forward | TTM | Forward | |
| Timeframe | ||||||||||
| 1 Year | – | -0.51% | – | -0.63% | – | 0.49% | – | 0.21% | – | 93.1% |
| 3 Years | – | -0.51% | – | -0.63% | – | 0.49% | – | 0.21% | – | 93.1% |
| 5 Years | – | -0.51% | – | -0.63% | – | 0.49% | – | 0.21% | – | 93.1% |
| 10 Years | – | -0.51% | – | -0.63% | – | 0.49% | – | 0.21% | – | 93.1% |